A5021551704- Head and Neck Cancer Studies
- Advanced Radiotherapy Techniques
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Oral health in cancer treatment
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Advances in Oncology and Radiotherapy
- Head and Neck Surgical Oncology
- Radiomics and Machine Learning in Medical Imaging
- Radiation Therapy and Dosimetry
- Salivary Gland Tumors Diagnosis and Treatment
- Telomeres, Telomerase, and Senescence
- Effects of Radiation Exposure
- Management of metastatic bone disease
- Glioma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Endometrial and Cervical Cancer Treatments
- Esophageal Cancer Research and Treatment
- Neuroblastoma Research and Treatments
Vall d'Hebron Hospital Universitari
2015-2024
Vall d'Hebron Institute of Oncology
2019-2024
St. Luke's International Hospital
2019
University of Castilla-La Mancha
2013-2018
The Netherlands Cancer Institute
2016
Universitat Autònoma de Barcelona
1991-2015
Merck (Germany)
2015
The University of Texas MD Anderson Cancer Center
2007-2015
University of Wisconsin–Madison
2015
Maastro Clinic
2015
We conducted a multinational, randomized study to compare radiotherapy alone with plus cetuximab, monoclonal antibody against the epidermal growth factor receptor, in treatment of locoregionally advanced squamous-cell carcinoma head and neck.
We compared concomitant cisplatin and irradiation with radiotherapy alone as adjuvant treatment for stage III or IV head neck cancer.
Purpose To report the impact of radiotherapy quality on outcome in a large international phase III trial evaluating with concurrent cisplatin plus tirapazamine for advanced head and neck cancer. Patients Methods The protocol required interventional review plans by Quality Assurance Review Center (QARC). All documentation underwent post-treatment Trial Management Committee (TMC) compliance. Secondary noncompliant predicted tumor control was performed. Factors associated poor compliance were...
Purpose Promising results in a randomized phase II trial with the hypoxic cytotoxin tirapazamine (TPZ) combined cisplatin (CIS) and radiation led to this III trial. Patients Methods previously untreated stage or IV (excluding T1-2N1 M1) squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, larynx were randomly assigned receive definitive radiotherapy (70 Gy 7 weeks) concurrently either CIS (100 mg/m 2 ) on day 1 weeks 1, 4, (75 plus TPZ (290 /d) alone (160 days 3, 5 3 (TPZ/CIS)....
To compare event-free survival (EFS), overall (OS), pattern of relapse, and hearing loss in children with standard-risk medulloblastoma treated by postoperative hyperfractionated or conventionally fractionated radiotherapy followed maintenance chemotherapy.In all, 340 age 4 to 21 years from 122 European centers were postoperatively staged randomly assigned treatment (HFRT) standard (conventional) (STRT) a common chemotherapy regimen consisting eight cycles cisplatin, lomustine,...
We conducted a retrospective evaluation of the IMCL-9815 study to examine association human papillomavirus (HPV) and p16 protein expression status with outcomes in patients oropharyngeal carcinoma (OPC) receiving radiotherapy (RT) plus cetuximab or RT alone.In study, were randomly allocated receive weekly alone. A subpopulation p16-evaluable OPC was retrospectively evaluated on basis locoregional control (LRC), overall survival (OS), progression-free (PFS). Evaluable samples from...
Because of the unprecedented disruption health care services caused by COVID-19 pandemic, American Society Radiation Oncology (ASTRO) and European for Radiotherapy (ESTRO) identified an urgent need to issue practice recommendations radiation oncologists treating head neck cancer (HNC) in a time limited resources heightened risk patients staff.
Purpose In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma the head and neck (SCCHN) after high-dose radiotherapy alone or combination cetuximab. Patients Methods stage IV nonmetastatic measurable oropharynx, hypopharynx, larynx were eligible. QoL using European Organisation for Research Treatment Cancer Quality Life Questionnaire C30 (EORTC QLQ-C30) EORTC QLQ Head Neck Cancer–Specific Module at baseline,...
5507 Background: The majority of head and neck cancers overexpress the epidermal growth factor receptor (EGFR), which is associated with aggressive tumor behavior poor clinical outcome. Preclinical in vitro vivo model systems demonstrate radiosensitization following molecular inhibition EGFR signaling. Promising phase I/II results were achieved when radiation was combined blocking antibody, cetuximab, patients locoregionally advanced squamous cell carcinoma (SCC) (H&N). This III...
INTRODUCTION Severe diarrhea may complicate pelvic radiotherapy and force interruption of treatment. As there is no current clinical or experimental information on the role gut microbiota in this pathogenesis, we conducted a pilot observational study fecal patients receiving radiotherapy. METHODS The involved 10 who underwent 5 wk for abdominal tumors controls. Four samples were collected from each individual: before, during, at end, 2 after Following amplification bacterial 16S rRNA gene...
Radiochemotherapy of head and neck cancer causes severe mucositis in most patients. We investigated whether palifermin reduces this debilitating sequela.We conducted a multicenter, double-blind, randomized, placebo-controlled trial 186 patients with stages II to IVB carcinoma the oral cavity, oropharynx, hypopharynx, or larynx. Patients received 60 66 Gy after complete (R0) incomplete resection (R1), respectively, at 2 Gy/fraction five fractions per week. Cisplatin 100 mg/m(2) was...
<h2>Abstract</h2><h3>Background</h3> The use of chemotherapy to manage newly diagnosed low grade glioma (LGG) was first introduced in the 1980s. One randomised trial has studied two- versus four-drug regimens with a duration 12 months treatment after resection. <h3>Methods</h3> Within European comprehensive strategy for childhood LGG, International Society Paediatric Oncology–Low Grade Glioma (SIOP LGG) Committee launched involving 118 institutions and 11 countries investigate addition...
Failure of locoregional control is the main cause recurrence in advanced head and neck cancer. This multi-center trial aims to improve outcome two ways. Firstly, by redistribution radiation dose metabolically most FDG-PET avid part tumour. Hereby, a biologically more effective distribution might be achieved while simultaneously sparing normal tissues. Secondly, improving patient selection. Both cisplatin Epidermal Growth Factor Receptor (EGFR) antibodies like Cetuximab combination with...
Abstract Senescence, a terminal cell proliferation arrest, can be triggered by oncogenes. Oncogene-induced senescence is classically considered tumor defense barrier. However, several findings show that, under certain circumstances, senescent cells may favor progression because of their secretory phenotype. Here, we that the expression in different breast epithelial lines p95HER2, constitutively active fragment tyrosine kinase receptor HER2, results either increased or senescence. In cells,...